SCIENMAG: Medicine & Health

JANUARY 18, 2024

Reston, VA—A novel imaging approach, 68Ga-pentixafor PET/CT, has been shown to accurately identify sub-types of primary aldosteronism (an adrenal gland disorder), outperforming traditional methods for diagnosis.

Treatment 78

Treatment Doctors 78

Drug Target Review

DECEMBER 20, 2024

However, he believes that these fears will dissipate as pharma companies come to realise that AI firms like Unlearn adhere to stringent data control measures, ensuring the ethical use of patient information. In 2025, I think well see breakthroughs that allow us to make significant advances in rare diseases, where the data is small.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Covalent Modifiers

APRIL 18, 2024

This breakthrough led to the development and approval of sotorasib (AMG510) and adagrasib (MRTX849), revolutionizing the treatment of KRASG12C-dependent lung cancer. Insights from successful KRASG12C targeting informed the design of molecules addressing other mutations, often in a covalent manner.

Therapies 214

Therapies Treatment 214

Conversations in Drug Development Trends

MARCH 12, 2024

Biomarkers provide a rapid way to inform many clinical oncology study development decisions, including study endpoints. They can inform intervention outcomes, serve as study endpoints, and are advantageous across the spectrum of cancer care. What are they, how do they work, and how can they benefit your oncology study?

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 18 Indeed, early-phase clinical studies exploring TsAbs in solid tumours have recently commenced.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Drug Hunter

AUGUST 15, 2023

On Sunday, it was disclosed that additional, likely on-target adverse findings were observed in a primate GLP study on long-term treatment with Merck’s second-generation LRRK2 inhibitors. Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Small Molecule 229

Small Molecule Trials Treatment Disease 229

Drug Target Review

OCTOBER 25, 2023

Their findings may result in new treatments for reproductive conditions. He stated that this could inform new treatments for reproductive conditions like recurrent pregnancy loss and preeclampsia. A human foetus contains genetic material from both parents, which makes it partly foreign to the pregnant person’s body.

Treatment 106

Treatment Virus Research Science 106

SCIENMAG: Medicine & Health

AUGUST 17, 2023

The study opens the door to new treatments and preventive measures for bone regeneration and osteoporosis research. A new study of the PhyloBone project of the University of Turku, Finland, identifies hundreds of non-collagenous proteins in the bone matrix that may play regulatory roles in bone formation and regeneration.

Treatment 88

Treatment Research 88

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes. They also found that patients’ CTAPs were dynamic and could change over time in response to treatment.

Treatment 96

Treatment RNA Hospitals Disease 96

Covalent Modifiers

MARCH 19, 2024

Thus, UCHL1 inhibitors could serve as a viable treatment strategy against these aggressive cancers. Additionally, we report a ligand-bound crystal structure of the most potent molecule in complex with UCHL1, providing insight into the binding mode and information for future optimization.

Fragment Screening 195

Fragment Screening Disease Treatment 195

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Conversations in Drug Development Trends

AUGUST 14, 2024

By: Simran Padam, Medical Director, Medical Affairs Personalized treatment approaches have emerged as pivotal in improving outcomes for hematological cancers. Hematological cancer cells can also develop resistance to therapies over time, reducing treatment effectiveness.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Perficient: Drug Development

DECEMBER 18, 2024

Clear and accessible communication methods help patients understand their health information, engage with their care, and make informed decisions. Clear and accessible communication ensures that all patients receive the information they need in a format they can understand, which is crucial for delivering equitable and effective care.

Treatment 52

Treatment 52

DrugBank

JULY 8, 2024

Revolutionizing Treatment Through the Skin with Transdermal Drug Delivery Systems The human skin, often perceived as a passive barrier to the external environment, holds potential as a route for drug administration. These fluctuations can lead to unwanted side effects or compromise the effectiveness of the treatment.

Treatment 78

Treatment Drugs Clinical Trials Engineering 78

Advarra

FEBRUARY 4, 2025

At a busy research site, a clinical trial is ready to launch but its stuck in limbo over a single paragraph in the informed consent form (ICF). While the trial waits for approval, patients who are eager for a new treatment face delay. Language relating to the potential cost of participation.

Clinical Trials 52

Clinical Trials Trials Compliance Therapies 52

Perficient: Drug Development

JANUARY 6, 2025

Universal design (UD) in healthcare ensures that facilities, services, and information are accessible to everyone, regardless of their physical abilities. This approach encompasses architectural designs, patient communication methods, and even the format of health information.

Compliance 52

Compliance Regulations Treatment Production 52

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 65

Therapies Treatment Vaccine FDA Approval 65

PLOS: DNA Science

SEPTEMBER 5, 2024

Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015. These findings can then be used to predict response to treatments as well as survival time. More information enables more treatment choices.

Treatment 71

Treatment FDA Approval DNA Small Molecule 71

Drug Patent Watch

DECEMBER 12, 2024

It allows us to make more informed decisions and identify opportunities that may have been overlooked using traditional methods.” Conducting Due Diligence Once potential targets are identified, thorough due diligence is crucial to validate the assessment and make informed in-licensing decisions.

Licensing 96

Licensing Licensing Drugs Biosimilars 96

Perficient: Drug Development

NOVEMBER 6, 2024

Individuals with cognitive disabilities may face challenges in understanding information, communicating, and navigating complex healthcare systems. Avoid medical jargon and use plain language to explain health conditions, treatments, and procedures. Visual aids can help patients understand complex information more easily.

Treatment 52

Treatment Production 52

H1 Blog

MARCH 3, 2025

But now we can really look at how providers are treating and deploying our field medical teams against our materials and tools that make the most sense to get the information where it needs to go. These valuable insights have allowed J&J to rethink its educational focus and make informed decisions.

Nurses 52

Nurses Trials Clinical Trials Treatment 52

FDA Law Blog: Biosimilars

JUNE 12, 2024

Gibbs — It’s been over a year and a half since Over-the-Counter (“OTC”) hearing aids became legal, and it’s not clear that they’ve made the difference in hearing loss treatment that Congress anticipated. (FDA While helpful background, it’s not new information. Koblitz & Jeffrey N.

FDA 111

FDA Regulations Treatment Licensing 111

Codon

NOVEMBER 3, 2024

In the 1924 novel, The Magic Mountain , Thomas Mann describes a sanatorium patient named Anton Ferge as he undergoes a painful tuberculosis (TB) treatment. Over time, the frequency of resistance gene variants in the population will continue increasing because only the bacteria lacking those variants will die with treatment.

Vaccine 92

Vaccine Trials Therapies Clinical Trials 92

Broad Institute

OCTOBER 3, 2024

Largest-ever genetic study of epilepsy finds possible therapeutic targets By Ari Navetta October 3, 2024 Breadcrumb Home Largest-ever genetic study of epilepsy finds possible therapeutic targets Scientists have uncovered new genetic links to different types of epilepsy, which could lead to more tailored treatments.

DNA 133

DNA Doctors Treatment Disease 133

Broad Institute

DECEMBER 18, 2023

But a new path for bringing treatments to patients is starting to emerge. One of our long abiding concerns has been the pharmaceutical industry's progressive exit from R&D on treatments for central nervous system disorders apart from Alzheimer's and for large companies a nearly complete exit from new research in psychiatry.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Drug Target Review

JANUARY 12, 2024

How does the integration of Real-World Data (RWD) with genomic biomarker data contribute to a more comprehensive understanding of disease progression and treatment response? Based on the drugs mechanism of action, we can make informed decisions. This can lead to a new treatment being offered to the patient.

Doctors 111

Doctors Clinical Trials Treatment Therapies 111

Chemical Biology and Drug Design

SEPTEMBER 30, 2023

Abstract Epigenetic regulation of genes through posttranslational regulation of proteins is a well-explored approach for disease treatment, particularly in cancer chemotherapy. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes.

Regulations 100

Regulations Treatment FDA Disease 100

Chemical Biology and Drug Design

JANUARY 15, 2024

The expression levels of endoplasmic reticulum (ER) stress-related protein and silent information regulator 1/nuclear factor kappa-B (Sirt1/NF-κB) signaling pathway were used to observe the therapeutic effect of naringin. Cardiac tissue damage and fibrosis caused by 20 Gy XR were significant improved after NG treatment.

Disease 100

Disease International Regulations Treatment 100

Broad Institute

SEPTEMBER 23, 2024

The overarching goal of our project is to create treatments that utilize mRNA’s full potential as an informational molecule that can deliver any protein of interest,” said Hongyu Chen, a PhD student in Wang’s lab and co-first author on the study with fellow PhD students Dangliang Liu and Abhishek Aditham.

RNA 134

RNA Vaccine Small Molecule Therapies 134

Broad Institute

NOVEMBER 25, 2024

Ladders to Cures (L2C) Accelerator By Maria Nemchuk November 25, 2024 Breadcrumb Home Ladders to Cures (L2C) Accelerator The Ladders to Cures (L2C) Accelerator aims to catalyze progress across the research ecosystem and accelerates advances leading to treatments and cures for patients with rare genetic diseases.

Clinical Trials 52

Clinical Trials Disease Trials Therapies 52

ASPET

JUNE 6, 2024

In keeping with NCCIH's natural product research priorities and in recognizing this gap in knowledge, NCCIH formally launched a research program in 2019 to expand research on the potential therapeutic benefit of minor cannabinoids and terpenes for the treatment of pain.

Research 100

Research Production Treatment 100

FDA Law Blog: Drug Discovery

JANUARY 30, 2025

This target completion date is informed by the natural history of the disease, availability of alternative treatment, anticipated recruitment timeline, and the projected timeline for efficacy analysis(es); 2) the sponsors progress and plans for postapproval conduct of the trial provide sufficient assurance to expect timely completion of the trial.

FDA 105

FDA Trials Disease Drugs 105

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

National Institute on Drug Abuse: Nora's Blog

AUGUST 28, 2024

Over the past two decades, substance use treatment admissions have increased among people aged 50 and over. Chronic pain is prevalent among older adults, and treatment for pain is less effective in this age group than it is in younger people; it negatively impacts quality of life and is a risk factor for cognitive decline and premature death.

Treatment 110

Treatment Research Disease Drugs 110

Conversations in Drug Development Trends

JANUARY 21, 2025

Therefore, processes that impact laboratory efficiency and data quality are essential and can confer time and cost savings and advance groundbreaking treatments for those in need. Bioanalysis to support drug development requires meticulous attention to detail across many clinic and laboratory disciplines.

Clinical Trials 78

Clinical Trials Laboratories Trials Drug Development 78

PPD

SEPTEMBER 16, 2024

Machine learning is a subset of AI that identifies patterns in large datasets, leveraging identifiable conditions or attributes that are needed to inform sample selection for trials and other prospective data. It identifies cases in instances where diagnosis codes and other information available in each database are too non-specific to do so.

Clinical Development 98

Clinical Development Clinical Trials Clinical Research Trials 98